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EDITORIAL

One Isn’t the Loneliest of Numbers: N-of-1 Trials

I

n this issue of Advances in Chronic Kidney Disease by
Guest Editors, Donald Molony and Joshua Samuels,
evidence-based medicine (EBM) once again comes to the
fore. This issue represents an encore of sorts, reinvigorating many of the concepts which they promoted with their
authors in Volume 19, Issue 1 of this journal, “EvidenceBased Nephrology.”
EBM emphasizes the utilization of evidence in a hierarchically oriented
fashion. The best evidence originates
from expertly designed studies that
become well-deﬁned and carefully conducted research trials, which are ideally
randomized, parallel grouped, and
blinded. Such evidence facilitates the
recommendations of guideline groups
who bear the burden of informing best
practice for large-scale populations.
When such studies are not readily available or infeasible within a given time,
EBM next gauges the epistemological
strength of meta-analyses and systematic reviews, eg, Cochrane Database
of Systematic Reviews (http://www.
cochranelibrary.com/). When such evidence is unavailable, weaker evidence
from weaker sources can only yield
weak recommendations such as casecontrol studies.
EBM represents an approach to teaching how medicine is to be practiced.1
EBM promotes excellent care of individual patients by their physicians. EBM is the clinician’s
guide to providing excellent care, ie, evidence-based decision making and practice. By its very nature, EBM cannot
be ﬂawless. High probability, on which many of EBM precepts are founded, permits one to do the best for a patient
in most cases when that particular patient represents most
patients. However, outlier patients are nearly always in
the heterogeneous mix of a well-planned, multisite study.
Representative of this group is the individual who deﬁes
the conclusions of a hallmark clinical trial. For example,
the multicenter, open-label, randomized, controlled study
Cardiovascular Outcomes in Renal Atherosclerotic Le-

sions (CORAL) compared medical therapy alone with
medical therapy plus renal artery stenting in patients
with atherosclerotic renal artery stenosis and elevated
blood pressure, chronic kidney disease, or both. The
rare, elderly patient with resistant, three-drug high blood
pressure who dramatically responds to renal artery stenting is the reason that the investigators of CORAL still had
to state, “From this result, it is clear that
medical therapy without stenting is the
preferred management strategy for the
majority of people with atherosclerotic
renal-artery stenosis.”2 The small but
ﬁnite amount of uncertainty intrinsic to
the study alters the language of the
conclusion from “for all people” to “for
the majority of people.”
To administer the best medicine to an
individual when there is an absence of
evidence (not evidence of absence), the
clinician usually relies on a lifetime of
experience or the experiences of colleagues. This approach is tried but not
necessarily true because opposite or
alternative approaches are rarely attempted, unless failure of treatment occurs. To
determine the optimal approach to the
“no evidence” circumstance, one may
adopt an “N-of-1” strategy because the
N-of-1 randomized trial ranks at the top
of the Hierarchy of Strength of Evidence
for Treatment Decisions list by Guyatt
and colleagues,3 which includes in descending order after the N-of-1 randomized trial, systematic reviews of randomized trials, single randomized trial,
systematic review of observational studies addressing
patient-important outcomes, single observational study
addressing patient-important outcomes, physiological
studies, and unsystematic clinical observations. The
patient-centeredness of the N-of-1 randomized trial
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approach was acknowledged as important by the American Medical Association and consequently assigned
CPT code 01030T as a personalized medicine test.
Although nephrologists have been steeped in physiology,
treatment assignment based on animal studies has been at
best imperfect: man has been a poor model for the rat.
N-of-1 trials have been used in psychology and education historically. Medically based N-of-1 trials have been
used previously to evaluate many common conditions:
histamine receptor blockers for non-ulcer dyspepsia; tricyclic antidepressants for ﬁbromyalgia; inhaled bronchodilators, inhaled steroids, and theophylline for chronic
airﬂow limitation; nonsteroidal anti-inﬂammatory drugs
and paracetamol for osteoarthritis; antihistamines for
atopic dermatitis; and enalapril for hypertension.4 The ingredients of the N-of-1 trial are not new, but its recipe
must be followed for successful implementation.
Study design is the ﬁrst and foremost and involves randomized, simple crossover, and replication. Namely, the
application of a treatment A would be randomized
against a treatment B, but this does not mean alternation.
For example, the design of the two-drug study might be
tested for the individual as ABBA or BAAB rather than
ABAB. An eight-period crossover design with two interventions could proceed as ABBABAAB, but the smallest
trial is represented as AB or BA—tantamount to what is
done in clinical practice daily when one agent as treatment for a speciﬁc condition is changed to a different class
of agent, with the exception that outcomes are not recorded in a scientiﬁcally rigorous manner. The number
and length of treatments are dependent on the time
required to obtain data on the outcomes of interest as
well as the nature of the interventions—a drug with a
rapid onset of action and rapid decay intrinsically requires
a less lengthy trial interval than an agent with slow onset
of action. More intervention periods reduce confounding
from lifestyle interventions but do not completely eliminate confounding factors while entailing greater expense
and obliging a longer time commitment for trial completion. The number of interventions would also be contingent to varying degrees on the statistical power
associated with the deﬁned number of interventions. An
additional problem is that of treatment carryover effects,
especially with biologically altering agents. This potential
predicament begs the question of whether a “washout”
period should be instituted. Answering this question
reasonably depends in part on whether these periods of
drug elimination render the patient susceptible to harm.
Blinding is important and involves the patient, treating
physician(s), and the clinical monitoring team.
The overarching premise of the N-of-1 trial is improvement in health care, but the overarching reality is
feasibility. Mahon and associates5 compared outcomes between groups of patients with irreversible chronic airﬂow
limitation by N-of-1 trials or standard practice. The study

explored whether value could be ascribed to the administration of theophylline following an uncertain conclusion
rendered by an open trial of these patients. In the end, the
N-of-1 trials informed practitioners that treatment
without theophylline was reasonable in patients with
limited airway ﬂow. Furthermore, physicians who participated in N-of-1 trials also gained conﬁdence regarding
decision making after completion of the study. The cost
to conduct the N-of-1 trial was considered reasonable
and essentially equal to standard clinical practice.
Although relatively few have hopped onto the N-of-1
bandwagon, the ride is now easier because one may
customize N-of-1 trials. The pharmacy beneﬁt manager,
Opt-e-scrip, Inc. (Bedminster, NJ), offers personalized
medicine formularies by essentially establishing valid,
single-patient clinical trials. In brief, they build an N-of1 drug kit with instructions, having developed patented,
personalized medicine tests that determine drug efﬁcacy
in individual patients to optimize drug prescribing.
Certainly, N-of-1 is not for everyone, but the N-of-1 trial
is a viable alternative for those patients for whom no
drug appears effective or for those who seek the best
drug for them. If successfully used in tandem with pharmacogenomics, N-of-1 has the potential to truly personalize medicine and achieve our aspirational goal.
One is the loneliest number that you’ll ever do.
—Harry Nilsson
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